Days after Merck deal, Sutro rolls out $85M E round to fund internal cancer pipeline

Just days after announcing a deal with Merck, South San Francisco’s Sutro BioPharma is trotting out a sizable infusion of cash today to fuel its own internal pipeline of cancer drugs.